Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster administration and broader access to immunotherapy.

A subcutaneous injection that can administer an immunotherapy in 1–2 minutes using domestic technology has been developed and approved in the United States. Immunotherapies are usually given ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s disease.

The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab (Keytruda Qlex) formulated with berahyaluronidase alfa (MK-3475A) across all ...

Ozempic (semaglutide) is injected once weekly under the skin of your abdomen, upper arm, or thigh. Your doctor will show you how to do this before your first dose. To prevent skin issues, rotate your ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J., September 19, ...

- In preclinical studies presented today at the RNA Leaders USA Congress 2025, investigational ARO-MAPT demonstrated potent and long-lasting MAPT mRNA and Tau protein suppression with uniform ...